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Abstract
Background: Sedation with a2-agonists in the horse is reported to be accompanied by
impairment of arterial oxygenation. The present study was undertaken to investigate pulmonary gas
exchange using the Multiple Inert Gas Elimination Technique (MIGET), during sedation with the a2-
agonist detomidine alone and in combination with the opioid butorphanol.
Methods: Seven Standardbred trotter horses aged 3–7y e a r sa n dw e i g h i n g3 8 0 –520 kg, were
studied. The protocol consisted of three consecutive measurements; in the unsedated horse, after
intravenous administration of detomidine (0.02 mg/kg) and after subsequent butorphanol
administration (0.025 mg/kg). Pulmonary function and haemodynamic effects were investigated.
The distribution of ventilation-perfusion ratios (VA/Q) was estimated with MIGET.
Results: During detomidine sedation, arterial oxygen tension (PaO2) decreased (12.8 ± 0.7 to
10.8 ± 1.2 kPa) and arterial carbon dioxide tension (PaCO2) increased (5.9 ± 0.3 to 6.1 ± 0.2 kPa)
compared to measurements in the unsedated horse. Mismatch between ventilation and perfusion in
the lungs was evident, but no increase in intrapulmonary shunt could be detected. Respiratory rate
and minute ventilation did not change. Heart rate and cardiac output decreased, while pulmonary
and systemic blood pressure and vascular resistance increased. Addition of butorphanol resulted in
a significant decrease in ventilation and increase in PaCO2. Alveolar-arterial oxygen content
difference P(A-a)O2 remained impaired after butorphanol administration, the VA/Q distribution
improved as the decreased ventilation and persistent low blood flow was well matched. Also after
subsequent butorphanol no increase in intrapulmonary shunt was evident.
Conclusion: The results of the present study suggest that both pulmonary and cardiovascular
factors contribute to the impaired pulmonary gas exchange during detomidine and butorphanol
sedation in the horse.
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The possibility of producing potent sedation of horses by
alpha-2-adrenoreceptor agonists (a2-agonists) is one of
the greatest improvements in modern equine practice.
The dose-dependent sedation and analgesia produced by
the a2-agonists is reliable for diagnostic procedures and
for treatment of various conditions. The central action of
the a2-agonist is a presynaptic inhibition of noradrena-
line accompanied by a decreased sympathetic tone [1].
Alpha-2-agonists also exert physiological effects by their
action on peripheral a2-receptors [2]. Besides the well
recognised and potent cardiovascular changes, sedation
with a2-agonists in the horse is reported to be
accompanied by impairment of pulmonary gas exchange
and arterial oxygenation [3-6]. From the studies reported
in the horse to date, it is not possible to separate the
relative contributions of pulmonary and cardiovascular
alterations to the development of impaired arterial
oxygenation.
Horses that are deeply sedated with an a2-agonist are not
unconscious. A sedated horse must be handled with
caution, since it may be aroused by stimulation and can
respond with dangerous kicks [7-9]. In a situation in
which a painful procedure is planned or local analgesia
n e e d st ob ep l a c e db e f o r es u r g e r yo nt h es t a n d i n gh o r s e ,
accentuation of both sedation and analgesia can be
achieved by adding an opioid to the a2-agonist
[4,10,11]. Butorphanol, a mixed opioid with agonistic
and antagonistic properties, has proven effective in such
a combination [3,4,12]. There are limited reports on the
respiratory effects of butorphanol alone or in combina-
tion with the a2-agonist detomidine in horses [5,11], but
the effects of the combination on pulmonary gas
exchange has not been clarified.
With the multiple inert gas elimination technique,
developed by Wagner et al. [13] and modified for use
in the standing horse [14], the pulmonary gas exchange
and a virtually continuous distribution of ventilation-
perfusion ratios can be studied.
The aim of the present investigation was to determine
the physiological effects, especially on the pulmonary
gas exchange, of sedation with detomidine alone and in
combination with butorphanol.
Methods
Horses
Seven Standardbred trotters (two mares and five geld-
ings) that were considered healthy on clinical examina-
tion were studied. Their mean weight was 457 kg (range
380–520 kg) and mean age 5 years (range 3–7y e a r s ) .
Food and water were withheld for approximately 3 hours
prior to the sedation procedure. The local Ethical
Committee on Animal Experimental in Uppsala, Sweden
approved the experimental procedure.
Catheterisation
All catheterisations were performed with the horse
standing and unsedated, after local analgesia with
lidocaine (Xylocain® 2%, Astra, Sweden). A catheter
was introduced percutaneously into the transversal facial
artery (18G, Hydrocath TM arterial catheter, Omeda,
UK) for systemic arterial blood pressure measurements
and collection of arterial blood. A 100 cm pigtail catheter
(Cook Europe A/S, Söborg, Denmark) for injection of ice
cold saline during thermodilution measurements was
introduced by the same technique into the right jugular
vein, advanced to the right ventricle and then retracted
into the right atrium under pressure-tracing guidance. A
thermodilution catheter (7F, Swan-Ganz, Edwards lab.,
Santa Ana, CA, USA) was inserted with an introducer kit
(8F, Arrow Int. Inc., Reading, PA, USA) into the right
jugular vein and advanced into the pulmonary artery for
mixed venous blood sampling and measurements of
core temperature and pulmonary arterial blood pressure.
Once correctly placed, the catheters were locked in
position with Luer-lock adapters. Further, two infusion
catheters (14G, Intranule, Vygone, France) were placed
in the left jugular vein.
Protocol
Detomidine 0.02 mg/kg (Domosedan® vet., 10 mg/ml,
Orion Pharma Animal Health, Sollentuna, Sweden) was
given intravenously (IV), followed 20 minutes later by
butorphanol 0.025 mg/kg IV (Torbugesic®, 10 mg/ml, Fort
Dodge Animal Health, Fort Dodge, IA, USA). Sampling of
blood and expired gas for measurements of gas concentra-
tions by the multiple inert gas elimination technique
(MIGET) were performed in the unsedated standing horse
(Unsedated) and started 15 minutes after the detomidine
injection (Detomidine) and 15 minutes after the butorpha-
nol injection (Detomidine + Butorphanol). The order of
the measurements was the same on each occasion,
haemodynamic parameters followed by pulmonary func-
tion and gas exchange, and the sampling was completed in
5 minutes.
Measurements of haemodynamic parameters
Systemic arterial and pulmonary arterial blood pressure
(SAP and PAP) were measured by connecting the arterial
catheters via fluid-filled lines to calibrated pressure
transducers (Baxter Medical AB, Eskilstuna, Sweden)
positioned at the level of the scapulo-humeral joint.
Blood pressure and electrocardiogram (ECG) were
recorded on an ink-jet recorder (Sirecust 730, Siemens-
Elema, Solna, Sweden). Heart rate (HR) was recorded
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the thermodilution technique (Cardiac Output Compu-
ter Model 9520A, Edwards lab., Santa Ana, CA, USA). A
bolus of 20 ml ice cold 0.9% saline was rapidly injected
into the right atrium through the pigtail catheter
(injection time 3 sec), and the blood temperature was
then measured in the pulmonary artery at the tip of the
Swan-Ganz catheter and the cardiac output was com-
puted from the recorded temperature change. The mean
of at least three consecutive measurements was used.
Measurements of pulmonary function and gas exchange
Respiratory rate (RR) was measured by observing the
costo-abdominal movements, and expired minute venti-
lation (VE) was measured with a Tissot spirometer, range
0.5–685 l (Collins inc., Braintree, MA, USA) attached to
the nose mask. Oxygen uptake (VO2)w a sd e t e r m i n e db y
analysing gas from mixed expired air with a calibrated
gas analyser (Servomex, Sussex, UK, integrated into an
Oximeter 3200, Isler Bioengineering AG, Switzerland).
Volume and gas parameters are measured at body
temperature and pressure saturated (BTPS). Arterial (a)
and mixed venous (v) blood samples for measurements
of oxygen and carbon dioxide tensions (PaO2,P v O 2,
PaCO2,P v C O 2) and oxygen saturation of haemoglobin
(SaO2,S v O 2) were drawn simultaneously and anaerobi-
c a l l yi n t oh e p a r i n i s e ds y r i n g e sa n ds t o r e do ni c eu n t i l
analysed (within 30 minutes) by means of conventional
electrode techniques with correction of the p50 value
(ABL 300 and Hemoxymeter OSM 3, Radiometer,
Copenhagen, Denmark). Haemoglobin concentration
[Hb] was determined spectrophotometrically (Ultrolab
system, 2074 Calculating Absorptiometer LKB Clinicon,
Bromma, Sweden).
The distribution of ventilation and perfusion was
estimated by the multiple inert gas elimination techni-
que [13,14]. Six gases (sulphur hexafluoride, ethane,
cyclopropane, enflurane, diethyl ether and acetone),
inert in the sense of being chemically inactive in blood,
were dissolved in isotonic Ringer acetate solution
(Pharmacia, Stockholm, Sweden) and infused continu-
ously into the jugular vein at 30 ml/min from at least 40
minutes before baseline measurements until the collec-
tion of the last samples, 15 minutes after butorphanol
injection. Arterial and mixed venous blood samples were
drawn and simultaneously mixed expired gas was
collected from a heated mixing box connected to a
nose mask. Gas concentrations in the blood samples and
expirate were measured by the method of Wagner et al.
[15], using a gas chromatograph (Hewlett Packard 5890
series II, Atlanta, GA, USA). The arterial/mixed venous
and mixed expired/mixed venous concentration ratios of
each gas (retention and excretion, respectively) depend
on its blood-gas partition coefficient and the VA/Q (the
ratio of alveolar ventilation, VA and cardiac output, Q) of
the lung. The retention and excretion were calculated for
each gas, and the solubility of each gas in blood was
measured in each horse by a two-step procedure [15].
The solubilities were similar to those reported previously
[14]. These data were then used for deriving the
distribution of ventilation and blood flow in a 50-
compartment lung model, with each compartment
having a specific alveolar ventilation/blood flow ratio
(VA/Q ratio) ranging from zero to infinity. Ventilation
and blood flow in healthy subjects have a log normal
distribution against VA/Q ratios. Of the information
obtained concerning the VA/Q distribution, data are
presented for the mean and standard deviation of the
blood flow log distribution (Qmean and log SDQ,
respectively), shunt (perfusion of lung regions with
VA/Q < 0.005), and the mean and standard deviation
of the ventilation log distribution (Vmean and log SDV,
respectively). All subdivisions of blood flow and
ventilation are expressed in per cent of cardiac output
and expired minute ventilation, respectively. The differ-
ence between measured PaO2 and PaO2 predicted from
MIGET-algorithms on the basis of the amount of
ventilation-perfusion mismatching and shunt was deter-
mined. A higher predicted than measured PaO2 may
reflect diffusion limitation or extrapulmonary shunt.
Calculations and statistics
From the measurements obtained the following calcula-
tions were made, using standard equations. Stroke
volume (SV), systemic vascular resistance (SVR) and
pulmonary vascular resistance (PVR) as follows:
SV Qt HR = /
SVR mean SAP Qt = /
PVR mean PAP diastolic PAP Qt =− () /
Diastolic PAP was used in the formula as a substitute for
wedge pressure.
For the following calculations, blood gas values mea-
sured at 37°C were used.
Alveolar oxygen partial pressure: PAO2 =( P IO2 -
(PaCO2/R))
(R = Respiratory exchange ratio = 0.8), where PIO2 =
partial pressure of inspired O2.
The alveolar – arterial oxygen tension difference(P(A-a)O2)
was calculated.
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end-capillary pulmonary (ć) blood:
CzO2 = (Hb concentration × 1.39 × oxygen saturation of
Hb) + (PzO2 ×0 . 0 0 3 ) ,w h e r ez=a ,v ,ć.P ćO2 ≈ PAO2.
Arterial-mixed venous oxygen content difference (C(a-v)
O2)=C a O 2 -C v O 2.
Oxygen delivery: O2-del = CaO2 ×Q t .
Cardiac output (Qt) was also computed through mass
balance from measured VO2 and the arterio-venous oxygen
(or inert gas) content difference (the Fick principle). The
cardiac output measurements presented in Table three are
based on thermodilution measurements.
For statistical analysis the Statistica 6.0 software package
(Statsoft Inc., Tulsa, OK, USA) was used. The data were
analysed in a General Linear Model with repeated measures
ANOVA. When the ANOVA indicated a significant differ-
ence, Tukey's HSD post hoc test was used to determine at
whattimepointthereweresignificantdifferenceswithinthe
protocol from baseline and sedation, unless Mauchley's
sphericity test indicated significance. In this instance, a
planned comparison was applied to define the contrast at
eachtreatment[16].Ap-valuelessthan0.05wasconsidered
significant. Results are given as mean values ± SD.
Results
Data on ventilation and blood gases are presented in
Table 1, pulmonary gas exchange based on inert gas data
in Table 2 and circulation in Table 3.
Unsedated horse
In the unsedated, standing horse, circulatory data as well as
ventilation andpulmonarygas exchange (Tables1,2 and3)
were all within normal limits [14]. The distribution of
ventilation and perfusion was centered upon a VA/Q ratio
of approximately 1 (Qmean = 0.79) in all horses (Figure 1,
Table 1: Circulatory data (n = 7)
Unsedated Detomidine Detomidine-butorphanol GLM – ANOVA
HR Beats/min 38 ± 8 23 ± 5* 29 ± 5* p < 0.001
Qt ml/min × kg 72 ± 14 32 ± 10* 44 ± 6* p < 0.001
SV ml/kg × beat 2.0 ± 0.7 1.4 ± 0.6 1.5 ± 0.3 NS
SAP mean mmHg 116 ± 15 148 ± 14* 137 ± 14* p < 0.001
PAP mean mmHg 26 ± 2 34 ± 3* 31 ± 4* p < 0.001
SVR mmHg/ml/min × kg 1.69 ± 0.49 5.01 ± 1.45* 3.16 ± 0.62 *† p < 0.001
PVR mmHg/ml/min × kg 0.15 ± 0.06 0.31 ± 0.16* 0.15 ± 0.06† p = 0.017
O2 del ml/min × kg 11.4 ± 2.6 5.1 ± 1.8* 6.5 ± 0.8* p < 0.001
C(a-v)O2 ml/100 ml 6.1 ± 0.8 8.5 ± 1.8* 7.3 ± 1.1 p = 0.002
Hb g/l 1.15 ± 1.0 1.18 ± 1.3 1.11 ± 1.2 NS (p = 0.062)
Data presented as mean ± SD for heart rate (HR), cardiac output thermodilution (Qt), stroke volume (SV), mean systemic arterial pressure
(SAP mean), mean pulmonary arterial pressure (PAP mean), systemic vascular resistance (SVR), pulmonary vascular resistance (PVR), oxygen delivery
(O2 del), arterial-mixed venous oxygen content difference (C(a-v)O2) and haemoglobin concentration (Hb). Results for General Linear
Model-ANOVA (GLM-ANOVA), p value for differences between the treatments, NS = non-significant. Differences between treatments are
presented with the abbreviations: * = significantly different from unsedated, † = significantly different from detomidine sedation.
Table 2: Ventilation and blood gases (n = 7)
Unsedated Detomidine Detomidine-butorphanol GLM – ANOVA
RR B r e a t h s / m i n 1 6±3 1 2±5 1 0±1 *† p = 0.032
VE ml/min × kg 163 ± 36 157 ± 42 114 ± 24* p = 0.031
VT ml/kg 8.6 ± 1.8 10.6 ± 3.5 10.1 ± 2.4 NS
PaCO2 kPa
(mmHg)
5.9 ± 0.3
(44.3 ± 2.2)
6.1 ± 0.2*
(46.1 ± 1.8)
6.4 ± 0.3* †
(47.7 ± 2.1)
p < 0.001
P(A-a)O2 kPa
(mmHg)
0.5 ± 0.4
(4.1 ± 2.8)
2.2 ± 0.7*
(16.6 ± 5.4)
2.3 ± 1.3*
(17.2 ± 9.7)
p < 0.001
PaO2 kPa
(mmHg)
12.8 ± 0.7
(95.7 ± 4.5)
10.8 ± 1.2*
(80.7 ± 8.7)
10.6 ± 1.4*
(79.2 ± 10.6)
p < 0.001
PvO2 kPa
(mmHg)
4.3 ± 0.3
(32.5 ± 2.6)
3.5 ± 0.5*
(26.0 ± 3.5)
3.6 ± 0.2*
(27.0 ± 1.7)
p < 0.001
VO2 ml/min × kg 3.2 ± 0.5 2.4 ± 0.6 2.9 ± 1.0 NS
Data presented as mean ± SD for respiratory rate (RR), expired minute ventilation (VE), tidal volume (VT), arterial carbon dioxide tension (PaCO2),
alveolar-arterial oxygen tension difference (P(A-a)O2), arterial oxygen tension (PaO2), mixed venous oxygen tension (PvO2) and oxygen uptake
(VO2). For other explanations see Table 1.
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low VA/Q were noted and in no case was the shunt larger
than 1.5% of cardiac output (Figure 1, top panel). The
overall log SDV was 0.55, centered around Vmean = 0.95.
Bimodal ventilation distribution with an additional mode
locatedwithinhighVA/Qratios(VA/Q> 10)wasseenintwo
of seven horses. Dead space (VA/Q > 100) (including
apparatus dead space, i.e. face mask and non-rebreathing
valves of approximately 1 litre) averaged 64%.
Detomidine sedation
Fifteen minutes after detomidine administration, respira-
tory rate and expired minute ventilation had not changed
significantly, but PaCO2 increased slightly but significantly
compared to the values in the unsedated horse (Table 1). P
(A-a)O2 increased and PaO2 and PvO2 decreased during
sedation(Table1).Theshuntremainedsmallbutthescatter
of VA/Q ratio increased as evidenced by a higher log SDQ.
The centre of the distribution of ventilation and perfusion
increased and Qmean and Vmean were significantly higher
than in the unsedated horse (Figure 1, middle panel).
Regions with high VA/Q ratios were observed in three
horses.ThepredictedPaO2comparedtothemeasuredPaO2
was slightly but significantly higher compared to values in
the standing horse. HR and Qt decreased while increases in
vascular resistance and mean SAP and PAP were noted
during sedation with detomidine. Second-degree atrio-
ventricular (AV) block was recorded during sedation in six
of seven horses. VO2 did not change, but oxygen delivery
decreased significantly and C(a-v)O2 was higher during
detomidine sedation compared to the values in the
unsedated horse.
Detomidine and butorphanol combination
Addition of butorphanol during the detomidine seda-
tion resulted in a significant decrease in respiratory rate,
and a small but significant increase in PaCO2 was
measured compared to that during detomidine sedation
alone (Table 1). Minute ventilation decreased signifi-
cantly compared to that in the unsedated horse. The
cardiovascular changes persisted but the vascular resis-
tance in both the pulmonary and the systemic circulation
d e c r e a s e dc o m p a r e dt od e t o m i d i n es e d a t i o na l o n e .
Ventilation-perfusion distribution improved and dead
space ventilation decreased compared to detomidine
sedation. No shunt was seen and the predicted and
measured PaO2 were similar. Qmean and Vmean did no
longer differ from the unsedated horse (Figure 1, bottom
panel). The alterations in P(A-a)O2,P a O 2 and PvO2,a s
well as HR, Qt and mean SAP and PAP, that developed
during detomidine sedation remained after addition of
butorphanol (Tables 1 and 3). Second-degree AV block
remained in five of the six horses which showed AV
block during detomidine sedation. C(a-v)O2 decreased
and did not longer differ from the unsedated situation.
Discussion
It is suggested in the present study that the impaired
pulmonary gas exchange during detomidine and butor-
phanol sedation in the horse originates from both
pulmonary and cardiovascular factors. These results are
influenced by time and the order of drug administration
since the complexity of performing MIGET, including
several physiological measurements, limits the frequency
of sampling. In the present investigation first MIGET
measurements during sedation was taken 15 minutes
after detomidine administration and subsequent MIGET
measurements during detomidine and butorphanol
sedation were taken 35 minutes after detomidine
administration. The most pronounced decrease in heart
rate during detomidine sedation has been reported
between 2–5 minutes after intravenous administration
Table 3: Ventilation/perfusion relationship (VA/Q) data (n = 7)
Unsedated Detomidine Detomidine-butorphanol GLM – ANOVA
Percentage perfusion of regions with: Shunt 1.1 ± 0.3 1.3 ± 0.4 1.1 ± 0.4 NS
Normal VA/Q 98.8 ± 0.4 98.5 ± 0.6 98.8 ± 0.4 NS
Percentage ventilation of regions with: Normal VA/Q 36.0 ± 5.2 30.8 ± 7.5 35.7 ± 7.1 NS
High VA/Q 0.3 ± 0.5 2.5 ± 3.8 1.6 ± 2.3 NS
Dead space 63.6 ± 5.1 66.5 ± 4.2 61.3 ± 4.4 † p = 0.047
Log SDQ 0.37 ± 0.09 0.45 ± 0.11* 0.41 ± 0.09 p = 0.002
Log SDV 0.55 ± 0.32 0.85 ± 0.64 0.80 ± 0.59 NS
Mean Q 0.79 ± 0.21 1.58 ± 0.32* 0.86 ± 0.18 † p < 0.001
Mean V 0.95 ± 0.16 2.8 ± 1.7* 1.2 ± 0.33 † p = 0.029
Data presented as mean ± SD. Log SDQ = logarithmic standard deviation of blood flow (Q) around Q mean (unit VA/Q ratio).); Shunt =
VA/Q < 0.005; normal VA/Q = 0.1 < VA/Q < 10. Log SDV = logarithmic standard deviation of ventilation (V) around V mean (unit VA/Q ratio); normal
VA/Q = 0.1 < VA/Q < 10; high VA/Q = 10 < VA/Q < 100; dead space = (inert gas) including apparatus dead space: VA/Q > 100.
For other explanations see Table 1.
Acta Veterinaria Scandinavica 2009, 51:22 http://www.actavetscand.com/content/51/1/22
Page 5 of 9
(page number not for citation purposes)0
1
2
3
4
5
6
7
8
9
0 0,01 0,1 1 10 100
/  /
Shunt =1.2%
PaO2 = 13.3 kPa
Qt = 36 l/min
VE = 81 l/min
log SDQ = 0.38
VD/VT = 59 %
0
1
2
3
4
5
6
7
8
9
0 0,01 0,1 1 10 100
/  /
Shunt =1.3%
PaO2 = 10.6 kPa
Qt = 14 l/min
VE = 75 l/min
log SDQ = 0.57
VD/VT = 72 %
0
1
2
3
4
5
6
7
8
9
0 0,01 0,1 1 10 100
/  /
Shunt =1.2%
PaO2 = 10.3 kPa
Qt = 21 l/min
VE = 49 l/min
log SDQ = 0.48
VD/VT = 64 %
Horse 444 kg
D
e
t
o
m
i
d
i
n
e
&
d
e
t
a
d
e
s
n
U
e
n
i
d
i
m
o
t
e
D
l
o
n
a
h
p
r
o
t
u
B
Ventilations-perfusion ratio
V
e
n
t
i
l
a
t
i
o
n
(
 
 
)
B
l
o
o
d
F
o
l
w
(
)
 
 
l
/
m
i
n
V
e
n
t
i
l
a
t
i
o
n
(
)
 
B
l
o
o
d
F
l
o
w
(
)
 
l
/
m
i
n
V
e
n
t
i
l
a
t
i
o
n
(
 
 
)
B
l
o
o
d
F
o
l
w
(
)
 
 
l
/
m
i
n
Ventilations-perfusion ratio
Ventilations-perfusion ratio
0
1
2
3
4
5
6
7
8
9
0 0,01 0,1 1 10 100
/  /
Shunt =1.2%
PaO2 = 13.3 kPa
Qt = 36 l/min
VE = 81 l/min
log SDQ = 0.38
VD/VT = 59 %
0
1
2
3
4
5
6
7
8
9
0 0,01 0,1 1 10 100
/  /
Shunt =1.2%
PaO2 = 13.3 kPa
Qt = 36 l/min
VE = 81 l/min
log SDQ = 0.38
VD/VT = 59 %
0
1
2
3
4
5
6
7
8
9
0 0,01 0,1 1 10 100
/  /
Shunt =1.3%
PaO2 = 10.6 kPa
Qt = 14 l/min
VE = 75 l/min
log SDQ = 0.57
VD/VT = 72 %
0
1
2
3
4
5
6
7
8
9
0 0,01 0,1 1 10 100
/  /
Shunt =1.3%
PaO2 = 10.6 kPa
Qt = 14 l/min
VE = 75 l/min
log SDQ = 0.57
VD/VT = 72 %
0
1
2
3
4
5
6
7
8
9
0 0,01 0,1 1 10 100
/  /
Shunt =1.2%
PaO2 = 10.3 kPa
Qt = 21 l/min
VE = 49 l/min
log SDQ = 0.48
VD/VT = 64 %
0
1
2
3
4
5
6
7
8
9
0 0,01 0,1 1 10 100
/  /
Shunt =1.2%
PaO2 = 10.3 kPa
Qt = 21 l/min
VE = 49 l/min
log SDQ = 0.48
VD/VT = 64 %
Horse 444 kg
D
e
t
o
m
i
d
i
n
e
&
d
e
t
a
d
e
s
n
U
e
n
i
d
i
m
o
t
e
D
l
o
n
a
h
p
r
o
t
u
B
Ventilations-perfusion ratio
V
e
n
t
i
l
a
t
i
o
n
(
 
 
)
B
l
o
o
d
F
o
l
w
(
)
 
 
l
/
m
i
n
V
e
n
t
i
l
a
t
i
o
n
(
 
 
)
B
l
o
o
d
F
o
l
w
(
)
 
 
l
/
m
i
n
V
e
n
t
i
l
a
t
i
o
n
(
)
 
B
l
o
o
d
F
l
o
w
(
)
 
l
/
m
i
n
V
e
n
t
i
l
a
t
i
o
n
(
)
 
B
l
o
o
d
F
l
o
w
(
)
 
l
/
m
i
n
V
e
n
t
i
l
a
t
i
o
n
(
 
 
)
B
l
o
o
d
F
o
l
w
(
)
 
 
l
/
m
i
n
V
e
n
t
i
l
a
t
i
o
n
(
 
 
)
B
l
o
o
d
F
o
l
w
(
)
 
 
l
/
m
i
n
Ventilations-perfusion ratio
Ventilations-perfusion ratio
Figure 1
Distribution of ventilation-perfusion ratio (VA/Q) in one horse (444 kg). The top panel represent the VA/Q
distribution in an unsedated horse (Unsedated). The middle panel represent the VA/Q distribution 15 minutes after
intravenous detomidine administration (Detomidine). The lower panel represent the VA/Q distribution 15 minutes after
additional intravenous injection of butorphanol (Detomidine & Butorphanol). Note the impaired arterial oxygen tension
(PaO2)d u r i n gs e d a t i o ni nt h em i d d l ea n db o t t o mp a n e l .D u r i n gs e d ation with detomidine, cardiac output (Qt) decreased and
there was an increase in ventilation-perfusion mismatch (broader base of ventilation-perfusion ratio and increased SD of blood
flow log distribution (log SDQ)) compared to the unsedated horse. The intrapulmonary shunt was minimal. During sedation
with detomidine and butorphanol, the impaired PaO2 was a result of persistent low cardiac output and an additional reduction
in expired minute ventilation (VE). After addition of butorphanol the distribution of VA/Q improved as the reduced ventilation
and persistent low blood flow matched well. No increase in intrapulmonary shunt was evident during subsequent butorphanol
administration.
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minutes after injection [8]. In Wagner et al. 1991 [17]
detomidine 0.02 mg/kg given intravenously resulted in a
significant but stable decrease in cardiac output and
respiratory rate compared to unsedated horses between
15 and 60 minutes after administration. In the reported
study by Wagner et al. 1991 [17], arterial oxygenation
was only significantly decreased at 5 and 15 minutes
after sedation. Systemic and pulmonary vascular resis-
tance started to diminish around 30–45 minutes after
detomidine injection. The measurements at 15 and 35
minutes after detomidine administration in the present
study are thus made at a fairly stable heart rate and
cardiac output conditions. The effects on pulmonary gas
exchange and oxygenation measured at 35 minuts after
sedation is most likely an effect of the additional
administration of butorphanol.
Unsedated horse
The good match between ventilation and perfusion in the
standing unsedated horse results in near optimal oxyge-
nation. The narrow distribution of perfusion, with
absence of low VA/Q regions, negligible intrapulmonary
shunt and no diffusion limitation of oxygen, were similar
to that found in previous studies [14,18]. The presence of
ah i g hV A/Q mode, which is usually seen in the resting
horse [14], was noted in two of the horses. Interestingly,
the horse is able to match ventilation and perfusion as
efficiently as young human adults [19,20] and better than
sheep [21] despite the fact that the horse has a high
vertical lung distance gradient. This shows that the
mechanisms for matching ventilation and perfusion are
highly efficient in the athletic horse. These mechanisms
are probably related to the lung structure and it is
proposed that the horse primarily depends for the
matching on hypoxic vasoconstriction, i.e. redistribution
of blood flow from regions of low ventilation to areas of
higher ventilation, by pulmonary vasoconstriction, with
onlyasmall contribution fromcollateralventilation [22].
Regional PVR is higher in dependent lung regions than in
upper ones in the standing horse [23] and this may
contribute to the good VA/Q match.
Detomidine sedation
The impaired pulmonary gas exchange and arterial
oxygenation during detomidine sedation in the present
study reconfirm previous observations during sedation of
horses with a2-agonists [3,17,24]. Although the report-
edly classic causes of an increased P(A-a)O2,n a m e l y
ventilation-perfusion mismatch, failure of alveolar-end
capillary diffusion equilibration and right-to-left vascular
shunt, have been proposed as presumable mechanisms,
extrapulmonary contributors, e.g. extrapulmonary shunt
and cardiac output alterations, are possible [17].
It has been reported that the physiological changes
induced by a2-agonist may be dose-dependent [17,25].
Also, since the physiological effects induced by
a2-agonists are transient, the choice of methodology
and time points for data sampling probably affect the
r e s u l t s .T h ed e t o m i d i n ed o s eo f0 . 0 2m g / k gu s e di nt h e
present study is a clinically effective sedative dose in most
horses [8]. The measurements of cardiovascular and
pulmonary function were performed at 15 minutes after
intravenous injection of the detomidine. The significant
increase in P(A-a)O2 was mainly attributed to increased
VA/Q mismatch as a reduction of cardiac output.
The cardiac output was reduced by 56% which is in line
with the literature [17,26]. Since, the cardiac output
measurement may be inaccurate during bradycardia with
AV block, cardiac output was both measured by
thermodilution and calculated according to the Fick
principle. The results were in good agreement. In the
present study no increase in either pulmonary shunt or
low VA/Q was evident in the horses (Figure 1). The
significantly increased VA/Q mismatch (log SDQ)
measured during sedation might be caused by a larger
vertical difference in perfusion. The shift of the VA/Q
distribution to a higher range of VA/Q ratios during
detomidine sedation (Figure 1) was caused by a
significant reduction in pulmonary perfusion with
unaltered ventilation.
In the healthy human or animal the expected response
on increased VA/Q mismatch is mitigated by an increase
in the overall lung VA/Q ratio, thereby increasing the
alveolar ventilation and raising both alveolar and arterial
PO2 [17,26,27]. The absence of ventilatory response to
the detomidine-induced hypoxaemia may be due either
to decreased ventilatory responsiveness or to decreased
receptor sensitivity. However, in the present study,
detomidine administration did not result in changes in
respiratory rate or minute ventilation. An unaffected
respiratory rate is in line with some reports, although
others have found a decreased or increased respiratory
rate in healthy detomidine-sedated horses [24,28].
Interestingly, Wagner et al. [17] reported that the
respiratory rate was significantly reduced 15 minutes
after sedation and remained low during the study period
of two hours. Also, the slightly increased PaCO2
s u g g e s t e dt h a tt h e r ew a ss o m ed e g r e eo fh y p o v e n t i l a t i o n .
The lack of a compensatory increase in alveolar ventila-
tion during sedation with a2-agonists means that the
arterial blood gases are not corrected. It has been
demonstrated that a2-adrenergic receptors are present
in the carotid body and that such agonists exert an
inhibitory influence on the chemoreceptor response to
hypoxia [29]. Further, dexmedetomidine administered
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to increased CO2, lasting for approximately 2 hours [30].
In agreement with earlier reports on a2-agonists [8,17],
sedation with a2-agonists was associated with a sig-
nificant increase in pulmonary and systemic arterial
blood pressure. Although the distribution of blood flow
from hypoxic regions in the lung to ventilated areas is
highly efficient in the pony [22], it is possible that the
elevated PAP may disturb this mechanism for matching
of the perfusion to ventilated areas and thereby also
contributes to impaired arterial oxygenation [31].
The slightly higher PaO2 predicted by the multiple inert gas
elimination technique (MIGET) compared to the measured
PaO2 may be due to diffusion limitation or extra-
pulmonary reasons. Diffusion limitation can be caused by
a limited gas equilibration time or by structural changes of
the alveolar-capillary interface. Diffusion limitation seems
unlikely as the cardiac output was not high enough to cause
time limited gas equilibration and no clinical signs of
pulmonary oedema were seen. Administration of the a2-
agonist dexmedetomidine to dogs has been shown to
decrease cardiac output with 50%, resulting in decreased
perfusion of skin and muscle without decrease in blood
flow to the heart [32]. Venous blood from the heart enters
the arterial circulation through the Thebesian vein, without
going through the lung and is not a part of the MIGET
measurements. Thus, the difference between predicted and
measured PaO2 during detomidine sedation may be due to
a proportionally larger contribution from the Thebesian
vein to the arterial circulation which lowers the PaO2.
A reduction in mixed venous PO2 from 4.3 to 3.5 kPa
accompanied the decrease in arterial oxygenation during
detomidine sedation in the present study. A reduction in
cardiac output decreases PvO2 when oxygen consumption
remains unchanged. Although there was a tendency for
increased haemoglobin concentration and oxygen carrying
capacity inthe blood duringdetomidine sedation thiseffect
was overridden by the pronounced decrease in cardiac
output. The final result was an overall decrease in oxygen
delivery to the tissue and increased oxygen extraction. The
reduced PvO2 further reduces PaO2 for the same degree of
ventilation-perfusion mismatch [33]. Thus, the slight but
significantly increased VA/Q mismatch measured during
sedation in the present study further aggravated the
pulmonary gas exchange, especially in the presence of
impaired perfusion.
Detomidine and butorphanol combination
This drug combination is reported to have minimal
effects upon the cardiovascular system [11] and usually
does not cause any circulatory changes beyond those
induced by the a2-agonist alone although there may be a
slight further respiratory depression [3,4]. In the present
study, the only clear effect on pulmonary gas exchange
by the combination of detomidine and butorphanol was
a further decrease in ventilation, with additional increase
in PaCO2. This finding is probably an effect of
butorphanol since the effect of the detomidine adminis-
tered intravenously 35 minutes earlier is most likely
diminished [17,28]. Lavoie et al. [5] found that a
combination of detomidine and butorphanol in healthy
horses as well as in horses with pre-existing respiratory
dysfunction affected the respiratory function.
In the present study the increased P(A-a)O2 persisted
when butorphanol was additionally administered but
the contribution of the causative factors changed. After
butorphanol administration, the VA/Q distribution
improved and both Qmean and Vmean were normal-
ised. The shift of VA/Q distribution to relatively lower
but normal range was achieved by the reduction in
ventilation, which now matched the reduced blood flow
(Figure 1). Interestingly, the fraction of dead space
ventilation was reduced compared to values during
sedation with detomidine alone. This possibly reflects
an improved distribution of blood flow, since vascular
resistance was reduced compared to the values during
detomidine sedation. This is in line with earlier
i n v e s t i g a t i o no ns e d a t i o ni nt h eh o r s e[ 1 7 ]t h a th a s
showed a reduction in vascular resistance over time.
Conclusion
The results of the present study suggest that both
pulmonary and cardiovascular factors contribute to the
impaired pulmonary gas exchange during detomidine
and butorphanol sedation in the horse. A significant
reduction in blood flow and increase in VA/Q maldis-
tribution are the major contributors to the alveolar-
arterial oxygen tension difference during sedation with
detomidine. After addition of butorphanol P(A-a)O2
remained impaired despite the improved VA/Q distribu-
tion. This was caused by decreased ventilation, induced
by the butophanol administration, which matched a
persistent low blood flow. No increase in intrapulmon-
ary shunt compared to unsedated horses was evident
during detomidine sedation or subsequent butorphanol
administration.
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